csl bulk influenza vaccine (split virion inactivated).
seqirus pty ltd - influenza virus haemagglutinin, quantity: 30 microgram/ml - injection, suspension - excipient ingredients: monobasic potassium phosphate; thiomersal; calcium chloride dihydrate; dibasic sodium phosphate; sodium chloride; potassium chloride; monobasic sodium phosphate; water for injections - indicated for the prevention of influenza caused by influenza virus, types a and b.
agrippal inactivated influenza (surface antigen) vaccine injection pre-filled syringe (without needle) 2015
seqirus pty ltd - influenza virus haemagglutinin -
quadrivalent influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes
split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (sanofi - influenza virus split virion - suspension for injection
h5n1 influenza vaccine
seqirus (nz) ltd - influenza virus type a haemagglutinin 30ug (pandemic influenza virus haemagglutinin) - suspension for injection - 30 mcg/0.5ml - active: influenza virus type a haemagglutinin 30ug (pandemic influenza virus haemagglutinin) excipient: aluminium as aluminium phosphate adjuvant calcium chloride dibasic sodium phosphate monobasic potassium phosphate monobasic sodium phosphate potassium chloride sodium chloride thiomersal water for injection - prophylaxis of influenza in an officially declared pandemic situation. the vaccine may only be marketed or distributed in accordance with the directive contained in the current version of the new zealand influenza pandemic action plan.
supemtek
sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - influenza, human - vaccines - supemtek is indicated for active immunization for the prevention of influenza disease in adults.supemtek should be used in accordance with official recommendations.
protech bronchi-shield iii bordetella bronchiseptica, canine adenovirus type 2 and parainfluenza vaccine
boehringer ingelheim animal health australia pty. ltd. - canine parainfluenza; bordetella bronchiseptica; canine adeno virus type 2 - misc. vaccines or anti sera - canine parainfluenza vaccine active 0.0 p; bordetella bronchiseptica vaccine-microbial active 0.0 p; canine adeno virus type 2 vaccine-viral active 0.0 p - immunotherapy - dog - over 8 weeks - bordetella bronchiseptica | canine adenovirus - type 2 | canine parainfluenza | canine cough syndrome | infectious tracheobronchitis
fluenz
medimmune llc - reassortant influenza virus (live attenuated) of the following strains:a/california/7/2009 (h1n1)pdm09 like strain, a/victoria/361/2011 (h3n2) like strain, b/massachusetts/2/2012 like strain - influenza, human; immunization - vaccines - prophylaxis of influenza in individuals 24 months to less than 18 years of age.the use of fluenz should be based on official recommendations.
nobilis influenza h5n2
ministry for primary industries - avian influenza type a, subtype h5n2 - avian influenza type a, subtype h5n2 0 vaccine - vaccine
flumist quadrivalent- influenza vaccine live intranasal spray
medimmune, llc - influenza a virus a/norway/31694/2022 (h1n1) live (attenuated) antigen (unii: fv9fgc9yzw) (influenza a virus a/norway/31694/2022 (h1n1) live (attenuated) antigen - unii:fv9fgc9yzw), influenza a virus a/norway/16606/2021 (h3n2) live (attenuated) antigen (unii: l7z42hp5rz) (influenza a virus a/norway/16606/2021 (h3n2) live (attenuated) antigen - unii:l7z42hp5rz), influenza b virus b/austria/1359417/2021 live (attenuated) antigen (unii: jv6nd6vmy5) (influenza b virus b/austria/1359417/2021 live (attenuated) - influenza a virus a/slovenia/2903/2015 (h1n1) live (attenuated) antigen 10000000 [ffu] in 0.2 ml - flumist® quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine [see description (11)] . flumist quadrivalent is approved for use in persons 2 through 49 years of age. do not administer flumist quadrivalent to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine [see description (11)] including egg protein, or after a previous dose of any influenza vaccine. do not administer flumist quadrivalent to children and adolescents through 17 years of age who are receiving aspirin therapy or aspirin-containing therapy because of the association of reye’s syndrome with aspirin and wild-type influenza infection [see drug interactions (7.1)] . risk summary flumist quadrivalent is not absorbed systemically following intranasal administration and maternal use is not expected to result in fetal exposure to the drug. clinical considerations disease-ass
flublok- influenza vaccine injection, solution
protein sciences corporation - influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen (unii: 69h0yj871t) (influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen - unii:69h0yj871t), influenza a virus a/hong kong/4801/2014 (h3n2) recombinant hemagglutinin antigen (unii: 2i1eol437m) (influenza a virus a/hong kong/4801/2014 (h3n2) recombinant hemagglutinin antigen - unii:2i1eol437m), influenza b virus b/brisbane/60/2008 recombinant hemagglutinin antigen (unii: 058u2312cr) (influenza b virus b/bri - influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen 45 ug in 0.5 ml - flublok is a vaccine indicated for active immunization against disease caused by influenza a virus subtypes and influenza type b virus contained in the vaccine. flublok is approved for use in persons 18 years of age and older. flublok is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine (see postmarketing experience [6.2] and description [11] ). pregnancy outcomes in women who have been exposed to flublok during pregnancy are being monitored. contact: protein sciences corporation by calling 1-888-855-7871. all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively. available data on flublok administered to pregnant women are insufficient to inform vaccine-associated risks in pregnant women. a developmental study of flublok has been performed in